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nosed with systemic fungal infections. METHODS:
Using the Cerner/Protocare Sciences hospital database
(01/00–03/01), patients with claims for either a systemic
fungal diagnosis (DX), oral/IV antifungal prescription
(RX), or both (DX/RX) were selected for evaluation 
of outcomes including mortality, length of stay (LOS),
and total hospital charges. Common comorbid conditions
were compared among these groups. RESULTS: Overall,
there were 492 cases of systemic fungal infections diag-
nosed in 451 patients. Urogenital candidiasis accounted
for the majority of encounters (range: 28% for DX/RX
to 40% for DX), followed by aspergillosis (14% for DX
to 25% for DX/RX) and disseminated candidiasis (2%
for DX to 25% for DX/RX). The most common prin-
cipal diagnoses were chemotherapy (3.5%) and acute
myeloid leukemia (2.6%). Microbiology was assessed in
1,253 encounters, of which 37% reported an isolate with
Candida albicans being most common (57%). A systemic
antifungal agent was prescribed in 69% of diagnosed
cases and in another 3421 episodes not accompanied by
a diagnosis code. Of the 3761 antifungal prescriptions,
oral ﬂuconazole was most commonly initiated (58%) 
followed by intravenous ﬂuconazole (22%) and conven-
tional amphotericin (9%). Mortality, average LOS and
median charges per encounter were: 4%, 9 days, $12,696
for the DX group; 14%, 26 days, $43,632 for RX group;
and 22%, 25 days, $43,207 for the DX/RX group,
respectively. There were no substantial differences in age
between comparator groups; however, the DX group had
more females (range: 49% for DX/RX to 67% female for
DX) and signiﬁcantly fewer comorbidities and high-risk
procedures performed. The most common comorbidities/
procedures of interest were concomitant antibiotic use
(93%), intravascular devices (21.7%) and bacteremia/
septicemia (17.7%). CONCLUSIONS: This study
demonstrates the signiﬁcant morbidity, mortality, and
economic burden associated with systemic fungal 
infections.
PIN8
LENGTH OF STAY AND ANTIFUNGAL
TREATMENTS COSTS IN PATIENTS WITH
SYSTEMIC MYCOSIS: DESCRIPTION AND
ASSOCIATED FACTORS
Peiró S1, Gómez G2, Rejas J3, Guadarrama I4, Blanca AB5
1Fundación Instituto de Investigación en Servicios de Salud,
Escuela Valenciana de Estudios para la Salud,Valencia, Spain;
2Fundación Instituto de Investigación en Servicios de Salud,
Valencia, Spain; 3Investigación de Resultados en Salud, División
Médica, Pﬁzer SA, Alcobendas, Madrid, Spain; 4División
Corporativa e Institucional, Pﬁzer SA, Alcobendas, Madrid,
Spain; 5Euroclin Institute, Pﬁzer, S.A, Alcobendas, Madrid, Spain
OBJECTIVE: To describe the length of stay, the drug
treatment costs and the diagnosis and therapeutic tests
costs in patients hospitalized with a serious fungal infec-
tion and to analyze the factors associated to them.
METHODS: A retrospective review of the clinical records
of 399 hospitalization episodes which included a diag-
nosis of systemic mycosis going into 17 Spanish hospi-
tals have been performed. The length of stay has 
been described as global and by the type of pathogen
(aspergillosis, candidemia, emphirical and other
pathogens), drug treatment costs and diagnosis tests. A
descriptive analysis of the costs is performed. RESULTS:
The average length of stay of the patients under study was
38,87 days. The average length of the antifungal treat-
ment was 19,93 days, with 15,42 for intravenous treat-
ment and 4,49 days for oral therapy. Candidemia
represented the 42,6% of the sample, 17,3% was for
aspergillosis, 34,1% for empiric treatment, and the
resting 6% for other fungal infections. Amphotericin B
was prescribed in 11,6% of the patients (with or without
adding azoles), Amphotericin B lipid complex in 16,8%,
Amphotericin B lisosomal in 23,6%, and exclusively
Azoles in 29,3%. 9,2% of episodes were treated with a
combination of conventional amphotericin B with the
lipid or liposomal formulation, and a 3,8% a combina-
tion of these last two. Average cost of antifungal therapy
was €4.240,39 (€2.838,87 to €5.641,91), with a wide
variety between hospitals, determined by the type of anti-
fungals prescribed. People aged over 65 years old (and
occasionally people under 16 years old) showed shorter
average days of total treatment, intravenous and oral.
Transplanted and immunocompromised patients showed
a longer time of treatment, and those with previous cor-
ticotherapy showed longer stays. CONCLUSIONS: The
cost of hospital antifungal therapy is high and it is deter-
mined by the type of antifungal selected. Clinical charac-
teristics of patients may inﬂuence the total cost of the
treatment and/or the length of stay.
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OBJECTIVE: A pharmacoeconomic analysis was carried
out comparing the efﬁcacy of two treatment options for
community acquired pneumonia (CAP): Telithromycin
and Clarithromycin. METHODS: Retrospective analysis
using a decision tree model. The efﬁcacy of the two treat-
ment options was estimated from a randomised, double-
blind clinical trial, in which 800mg/day of Telithromycin
was compared to 1,000mg/day of Clarithromycin in
patients with CAP (162 and 156 respectively). The utili-
sation of resources was captured in the clinical trial with
estimated Spanish sources, and the unit costs from a
